Current Osteoporosis Reports

, Volume 1, Issue 3, pp 123–128

Skeletal and nonskeletal effects of raloxifene

  • Oscar Gluck
  • Michael Maricic

DOI: 10.1007/s11914-996-0007-4

Cite this article as:
Gluck, O. & Maricic, M. Curr Osteoporos Rep (2003) 1: 123. doi:10.1007/s11914-996-0007-4


Raloxifene, a selective estrogen receptor modulator, is approved for the prevention and treatment of postmenopausal osteoporosis. Prevention studies with raloxifene have demonstrated preservation of bone density and suppression of bone turnover markers in young postmenopausal women. The Multiple Outcomes of Raloxifene Evaluation study was the pivotal treatment trial for raloxifene. It demonstrated significant reduction in the risk for vertebral fractures after 1 and 3 years. Significant reduction of nonvertebral fractures with raloxifene has not yet been demonstrated. In addition to the effects of raloxifene on bone, potentially beneficial effects on the cardiovascular system, breast, and uterus have been described. Most of these nonskeletal effects have been reported as secondary endpoints from large osteoporosis trials with raloxifene. Prospective, randomized, double-blind studies of raloxifene with breast cancer prevention and cardiovascular protection as primary endpoints are now underway.

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Oscar Gluck
  • Michael Maricic
    • 1
  1. 1.Southern Arizona VA Health Care SystemTucsonUSA

Personalised recommendations